Article
Oncology
Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson
Summary: This study investigated the efficacy and safety of NIZ985 as monotherapy and in combination with spartalizumab in the treatment of advanced solid tumors. The results showed that NIZ985 demonstrated antitumor activity and was well tolerated in patients with advanced solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Evangelos Terpos, Michalis Liontos, Oraianthi Fiste, Flora Zagouri, Alexandros Briasoulis, Aimilia D. Sklirou, Christos Markellos, Efthymia Skafida, Alkistis Papatheodoridi, Angeliki Andrikopoulou, Konstantinos Koutsoukos, Maria Kaparelou, Vassiliki A. Iconomidou, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos
Summary: This study aimed to investigate the immunogenicity of different vaccines in cancer patients receiving immunotherapy. The results showed that a third booster dose significantly optimized antibody responses. The study highlights the importance of large cohort studies to evaluate vaccine effectiveness and durability of protection in the real-world setting.
Article
Biology
Alejandro Olivares-Hernandez, Luis Figuero-Perez, Jose Pablo Miramontes-Gonzalez, Alvaro Lopez-Gutierrez, Rogelio Gonzalez-Sarmiento, Juan Jesus Cruz-Hernandez, Emilio Fonseca-Sanchez
Summary: The relationship between viral infections and cancer, as well as their impact on the immune system and response to immunotherapy in solid tumors, has been established through multiple studies. Viral infections, such as EBV and HPV, may enhance the response to immune checkpoint inhibitors and ultimately improve patient survival in certain solid tumors.
Review
Biochemistry & Molecular Biology
Yizhou Jiang, Limor Rubin, Tangming Peng, Linlin Liu, Xingan Xing, Philip Lazarovici, Wenhua Zheng
Summary: This review summarizes the mechanism of SARS-CoV-2 infection and the subsequent immunological events related to excessive cytokine production and inflammatory responses associated with ACE2-AngII signaling. An overview of the diagnosis and an update on current therapeutic regimens and vaccinations are also provided.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Review
Immunology
Konstantinos Tsiakos, Niki Gavrielatou, Ioannis A. Vathiotis, Loukas Chatzis, Stamatios Chatzis, Garyfallia Poulakou, Elias Kotteas, Nikolaos K. Syrigos
Summary: The immune system plays a crucial role in regulating immune responses, and immune checkpoint molecules are involved in both tumor and viral immune evasion. Studying the impact of immune checkpoint blockade on viral infections is important, and it could provide insight into the potential role of immunotherapy in treating viral infections.
Review
Pharmacology & Pharmacy
Yaqun Li, Wenjie Zhao, Jinhua Liu, Zichao Chen, Qingtao Lv, Zhen Zhang
Summary: COVID-19 pneumonia, caused by SARS-CoV-2, has disrupted the pro-inflammatory/anti-inflammatory response, leading to a need to neutralize cytokine storm. Current treatments focus on vaccines for prevention and immunomodulatory therapies to alleviate immune imbalance, with antiviral drugs and respiratory support as clinical options.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H. Johnson, Chrystia M. Zobniw, Van A. Trinh, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M. Elsayes, Kaysia Ludford, Emma J. Montazari, Julia Chernis, Maya Dimitrova, Sabina Sandigursky, Jeffrey A. Sparks, Osama Abu-Shawer, Osama Rahma, Uma Thanarajasingam, Ashley M. Zeman, Rafee Talukder, Namrata Singh, Sarah H. Chung, Petros Grivas, May Daher, Ala Abudayyeh, Iman Osman, Jeffrey Weber, Jean H. Tayar, Maria E. Suarez-Almazor, Noha Abdel-Wahab, Adi Diab
Summary: This retrospective study evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) therapy for immune-related adverse events (irAEs). The results showed that anti-IL-6R treatment can improve irAEs without hindering antitumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Multidisciplinary Sciences
Tareq Abu-Izneid, Noora AlHajri, Abdallah Mohammad Ibrahim, Md. Noushad Javed, Khairi Mustafa Salem, Faheem Hyder Pottoo, Mohammad Amjad Kamal
Summary: miRNAs play key roles in regulating gene expression, especially in viral infections, making them potential targets for novel therapeutic strategies. Modulation of immune-pathogenesis responses by miRNAs can either enhance or inhibit virus replication, highlighting their importance in viral infection treatment.
JOURNAL OF ADVANCED RESEARCH
(2021)
Article
Immunology
Sebastian Wurster, Nathaniel D. Albert, Uddalak Bharadwaj, Moses M. Kasembeli, Jeffrey J. Tarrand, Naval Daver, Dimitrios P. Kontoyiannis
Summary: ICIs have potential in treating mucormycosis, but their mechanism of action remains unclear. This study investigated the effects of PD-1 and PD-L1 inhibitors on IPM in immunosuppressed mice. The results showed that ICI treatment improved clinical outcomes of IPM in mice, with PD-L1 inhibition yielding more favorable immune responses and sustained protection. However, further research is needed to determine the optimal dosage.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Nikita Abramenko, Frederic Vellieux, Petra Tesarova, Zdenek Kejik, Robert Kaplanek, Lukas Lacina, Barbora Dvorankova, Daniel Rosel, Jan Brabek, Adam Tesar, Milan Jakubek, Karel Smetana
Summary: Estrogens may have a protective effect against COVID-19 by influencing the cardiovascular/pulmonary/immune system, reducing cytokine storms, and directly inhibiting viral replication. In addition to natural hormones, phytestrogens and synthetic molecules may also have anti-viral activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Infectious Diseases
Farhan Cyprian, Muhammad Umar Sohail, Ibrahim Abdelhafez, Salma Salman, Zakria Attique, Layla Kamareddine, Maha Al-Asmakh
Summary: By the beginning of 2020, COVID-19 caused by SARS-CoV-2 had become a global pandemic, mainly spread through the respiratory system and associated with various chronic diseases. Recent studies suggest that the pulmonary and gut microbiomes may modulate the course of COVID-19.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Oncology
Canling Lin, Yonghui Chen, Liji Shi, Huarong Lin, Hongmei Xia, Weihua Yin
Summary: Prostate cancer is a significant disease worldwide, and its incidence is increasing in China. Despite the efficacy of chemotherapy agents, treatment failure can occur, leading to castration-resistant prostate cancer. Due to limited treatment options, bio-immunotherapy targeting the prostate microenvironment has become an important option for advanced prostate cancer. This study investigates the role of three types of bio-immunotherapies in castrate-resistant prostate cancer, providing insights for clinical treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pfoehler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Loeffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimmer
Summary: This study analyzed the impact of NRAS gene mutations on melanoma patients treated with immune checkpoint inhibitors. The results showed that NRAS mutations were not significantly correlated with patients' survival and treatment response, and had no correlation with the expression of the T-cell immune checkpoint molecule PD-L1.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Christophe Zemmour, Brice Chanez, Anne Sophie Chretien, Laurent Gorvel, Gwenaelle Gravis, Damien Bruyat, Roxane Mari, Anne Madroszyk, Thomas Cuny, Anthony Goncalves, Aaron E. Lisberg, Daniel Olive, Louis Tassy, Frederic Castinetti, Philippe Rochigneux
Summary: Data mining analysis showed that immune checkpoint inhibitor (ICI)-induced dysthyroidism (DT) was associated with improved overall survival (OS), and patients with both DT and other immune-related adverse events had even longer OS.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Giandomenico Roviello, Luigi Francesco Iannone, Melissa Bersanelli, Enrico Mini, Martina Catalano
Summary: Immunotherapy has revolutionized cancer treatment, but reliable biomarkers for predicting treatment response are still unknown. Recent studies suggest that the gut microbiota may play a role in modulating the efficacy and toxicity of immunotherapy drugs.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Enrico Franceschi, Santino Minichillo, Alicia Tosoni, Maurizio Mascarin, Antonella Mura, Monica Di Battista, Vincenzo Di Nunno, Lidia Gatto, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes
Summary: The study found that treating average-risk medulloblastoma patients in a referral center significantly improved progression-free survival (PFS) and overall survival (OS), and the addition of adjuvant chemotherapy was also beneficial for survival.
Article
Pharmacology & Pharmacy
Lidia Gatto, Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
Summary: The clinical management of glioblastoma (GBM) lacks effective treatments, and there is a need for novel therapeutic drugs. The testing of multiple anticancer agents at the same time in clinical trials is critical for improving outcomes. Despite disappointing results with immune checkpoint inhibitors (ICIs), immunotherapy using engineered immune cells shows promise in treating GBM. This review discusses the challenges in planning clinical trials, interventional studies in previously untreated and recurrent GBM, and the potential of immunotherapeutic approaches.
Article
Medicine, General & Internal
Deborah Malvi, Francesco Vasuri, Thais Maloberti, Viviana Sanza, Antonio De Leo, Adele Fornelli, Michele Masetti, Claudia Benini, Raffaele Lombardi, Maria Fortuna Offi, Mariacristina Di Marco, Matteo Ravaioli, Sirio Fiorino, Enrico Franceschi, Alba A. Brandes, Elio Jovine, Antonietta D'Errico, Giovanni Tallini, Dario de Biase
Summary: Despite efforts, the 5-year survival rate for PDAC remains very low. Precision oncology is not yet ready for PDAC, despite studies on molecular and genetic alterations. This study used next-generation sequencing to analyze PDAC samples and found that KRAS and TP53 mutations were common, with KRAS mutation associated with shorter time to tumor recurrence.
Review
Immunology
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Alba Ariela Brandes
Summary: This review aims to summarize the current knowledge on hypermutation in high-grade gliomas and discusses the limitations of tumor mutational burden and mismatch repair deficiency as biomarkers for the response to immune checkpoint inhibitors.
Review
Oncology
Enrico Franceschi, Caterina Giannini, Julia Furtner, Kristian W. Pajtler, Sofia Asioli, Raphael Guzman, Clemens Seidel, Lidia Gatto, Peter Hau
Summary: Adult medulloblastoma is a rare tumor of the central nervous system with treatment primarily based on pediatric experience. Novel molecular advances and hub centers play a crucial role in improving the overall outcome of this disease.
Review
Oncology
Vincenzo Di Nunno, Caterina Giannini, Sofia Asioli, Alfredo Conti, Julia Furtner, Damiano Balestrini, Alicia Tosoni
Summary: Only 1% of meningioma cases are classified as malignant (anaplastic) meningioma. Due to their rarity, there are gaps in the clinical management of these tumors. This review investigates the current knowledge of anaplastic meningioma in terms of pathological and radiological diagnosis, molecular assessment, and treatment approaches. Surgery and radiation therapy play a crucial role in managing grade 3 meningioma, while systemic therapy is not widely used. It is anticipated that the increasing understanding of molecular pathways will lead to the development of more effective systemic treatments.
Review
Pharmacology & Pharmacy
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Alba Ariela Brandes
Summary: "Immunotherapy and targeted therapy for glioblastoma" summarizes the recent advancements in immunotherapy and targeted therapy for glioblastoma, including trial designs and combination therapies with immuno-oncology agents and targeted treatments. The molecular heterogeneity of glioblastoma and anatomical characteristics of the brain limit the effectiveness of drugs, but new treatment strategies such as multi-specific CAR-T therapy, oncolytic viral therapy, and autologous dendritic cell vaccination show promise for the future.
EXPERT OPINION ON DRUG DISCOVERY
(2023)
Review
Pharmacology & Pharmacy
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Caterina Tonon, Raffaele Lodi, Raffaele Agati, Stefania Bartolini, Alba Ariela Brandes
Summary: Glioblastoma (GBM) is a malignant brain tumor with high heterogeneity, leading to difficulties in treatment and prognosis. Radiogenomics, an emerging field, aims to study the correlation between radiographic features and gene expression. This review summarizes recent advancements in the use of magnetic resonance imaging (MRI) radiogenomics for assessing molecular markers related to prognosis and treatment response in GBM, as well as its potential efficacy in survival prognostication.
Letter
Oncology
Vincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Enrico Franceschi
Article
Oncology
Lidia Gatto, Vincenzo Di Nunno, Alicia Tosoni, Stefania Bartolini, Lucia Ranieri, Enrico Franceschi
Summary: Glioblastoma is the most common primary brain tumor with a poor prognosis. Current standard treatment involves surgery, radiotherapy, and chemotherapy. Despite advances in molecular biology, survival rates remain low. Immunotherapy has shown promise in treating glioblastoma, but further research is needed.
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.
